Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Cash & Equivalents (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Cash & Equivalents for 17 consecutive years, with $10.2 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 1.32% to $10.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 billion through Dec 2025, down 1.32% year-over-year, with the annual reading at $10.2 billion for FY2025, 1.32% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $10.2 billion at Bristol Myers Squibb, down from $15.7 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $15.7 billion in Q3 2025, with the low at $6.3 billion in Q2 2024.
  • Average Cash & Equivalents over 5 years is $10.5 billion, with a median of $10.5 billion recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 44.7% in 2021, then surged 100.21% in 2025.
  • Over 5 years, Cash & Equivalents stood at $14.0 billion in 2021, then crashed by 34.74% to $9.1 billion in 2022, then increased by 25.66% to $11.5 billion in 2023, then dropped by 9.75% to $10.3 billion in 2024, then decreased by 1.32% to $10.2 billion in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $10.2 billion, $15.7 billion, and $12.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.